| | 319460-85-0 Basic information More.. |
| Product Name: | Axitinib | | Synonyms: | N-METHYL-2-{[3-((E)-2-PYRIDIN-2-YLVINYL)-1H-INDAZOL-6-YL]SULFANYL}BENZAMIDE;AVERMECTINB;Axitinib for research;AG 013736;Benzamide, N-methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-;Axtinib;N-Methyl-2-({3-[(E)-2-(pyridin-2-yl)ethenyl]-1H-indazol-6-yl}sulfanyl)benzaMide;10MG/50MG/100G | | CAS: | 319460-85-0 | | MF: | C22H18N4OS | | MW: | 386.47 | | EINECS: | 638-771-6 | | Mol File: | 319460-85-0.mol |  |
Use
In January 2012, the US FDA approved axitinib (also referred to as
AG-013736) for the treatment of advanced renal cell carcinoma (RCC)
for patients who have not responded to prior therapy.
Axitinib is a pan VEGF inhibitor and functions by binding to
the intracellular tyrosine kinase catalytic domain of VEGF leading to blockade of signaling through this angiogenic pathway. Axitinib is50–400 times more potent for VEGF (enzyme Ki and cellular IC50s for VEGF 1, 2, and 3 are ～0.1 nM) than first-generation inhibitors like sorafenib and sunitinib. Axitinib also inhibits c-Kit and PDGFR(α/β) with enzyme Ki's of
～2 nM and was selective when tested against a broad panel of other protein
kinases. Axitinib was discovered by a structure-based drug design approach
and binds to the kinase domain of VEGF in a DFG-out conformation.
Axitinib blocks VEGF-2 phosphorylation up to 7 h postdose in vivo and
inhibits endothelial cell proliferation in xenograft tumors implanted in
mice. Synthetic routes to axitinib employing a Migita coupling to form
the diaryl sulfide and a Heck reaction to install the 2-styrylpyridine moiety have been reported.
- Axitinib
-
- US $33.00-61.00 / mg
- 2024-11-16
- CAS:319460-85-0
- Min. Order:
- Purity: 99.81%
- Supply Ability: 10g
- Axitinib
-
- US $1.00-0.50 / kg
- 2024-11-15
- CAS:319460-85-0
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 200
- Axitinib
-
- US $33.00-61.00 / mg
- 2024-11-15
- CAS:319460-85-0
- Min. Order:
- Purity: 99.81%
- Supply Ability: 10g
|
|
319460-85-0
Recommend Suppliers |
|